Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Group 1 - Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, at the Sheraton New York Times Square Hotel [1][2] - The company focuses on the development and commercialization of PEDMARK, aimed at reducing the risk of platinum-induced ototoxicity in pediatric patients [2] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [2] Group 2 - PEDMARK has Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [2]